The effects on cancer‐cell proliferation and differentiation mediated by peroxisome proliferator‐activated receptors (PPARs) have been widely studied, and pleiotropic outcomes in different cancer models and under different experimental conditions have been obtained. Interestingly, few studies report and little preclinical evidence supports the potential antitumor activity of PPAR antagonists. This review focuses on recent findings on the antitumor in vitro and in vivo effects observed for compounds able to inhibit the three PPAR subtypes in different tumor models, providing a rationale for the use of PPAR antagonists in the treatment of tumors expressing the corresponding receptors.

中文翻译：

---

过氧化物酶体增殖物激活受体拮抗剂的抗癌潜力

已经广泛研究了由过氧化物酶体增殖物激活受体（PPAR）介导的癌细胞增殖和分化的影响，并获得了在不同癌症模型和不同实验条件下的多效性结果。有趣的是，很少有研究报道，并且几乎没有临床前证据支持PPAR拮抗剂的潜在抗肿瘤活性。这篇综述集中在关于在各种肿瘤模型中能够抑制三种PPAR亚型的化合物在体外和体内抗肿瘤作用方面的最新发现，为在治疗表达相应受体的肿瘤中使用PPAR拮抗剂提供了理论依据。